First Response Fund News Today

News and Press Release in English on World about Health and Epidemic; published on 7 Jun 2024 by GAVI

Gavi is facing several important milestones in 2024: developing its next five-year strategy, known as “Gavi 6.0,” gearing up for its upcoming replenishment, and welcoming its new CEO. This year presents an opportunity for Gavi’s board and leadership to revisit its approach to ensure continued impact, even amidst resource constraints.

Recent approval by the Vaccine Alliance (Gavi) of a US$1.8 billion African Vaccine Manufacturing Accelerator (AVMA), a financing instrument that will support sustainable vaccine manufacturing in Africa is being hailed as a  game changer for the continent.

Nearly 18 months after the first administration of a COVID-19 vaccine, incredible progress has been made. Yet despite this progress, inequities between lower and higher income countries are continuing to cost lives and are prolonging the pandemic.

Vaccine: Over $1.8BN Mobilised in Support of Production in Africa

Gavi CEO David Marlow gives his reflections on the driving forces for progress in 2023 and what's in store for 2024.

Gavi, the vaccine alliance, says it has committed more than US$1.8 billion to support vaccine production in Africa, a move that could bolster the continent’s efforts to address historical dependence on imported vaccines and establish its own robust biotechnology sector.

Health leaders says Gavi funding of $US1.8bn will boost and help Africa achieve self-reliance in vaccine production.

The Board of Gavi, the Vaccine Alliance today approved the establishment of the African Vaccine Manufacturing Accelerator (AVMA), a financing instrument that